Target
eIF-2-alpha kinase GCN2
Ligand
BDBM50591056
Substrate
n/a
Meas. Tech.
ChEMBL_2199067 (CHEMBL5111583)
IC50
211±n/a nM
Citation
 Jackson, JJShibuya, GMRavishankar, BAdusumilli, LBradford, DBrockstedt, DGBucher, CBui, MCho, CColas, CCutler, GDukes, AHan, XHu, DXJacobson, SKassner, PDKatibah, GEKo, MYMKolhatkar, ULeger, PRMa, AMarshall, LMaung, JNg, AAOkano, APookot, DPoon, DRamana, CReilly, MKRobles, OSchwarz, JBShakhmin, AAShunatona, HPSreenivasan, RTivitmahaisoon, PXu, MZaw, TWustrow, DJZibinsky, M Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy. J Med Chem 65:12895-12924 (2022) [PubMed] 
Target
Name:
eIF-2-alpha kinase GCN2
Synonyms:
E2AK4_HUMAN | EIF2AK4 | Eukaryotic translation initiation factor 2-alpha kinase 4 | GCN2 | GCN2(Kin.Dom.2 S808G) | GCN2-like protein | KIAA1338
Type:
PROTEIN
Mol. Mass.:
186899.26
Organism:
Homo sapiens (Human)
Description:
ChEMBL_1495738
Residue:
1649
Sequence:
MAGGRGAPGRGRDEPPESYPQRQDHELQALEAIYGADFQDLRPDACGPVKEPPEINLVLYPQGLTGEEVYVKVDLRVKCPPTYPDVVPEIELKNAKGLSNESVNLLKSRLEELAKKHCGEVMIFELAYHVQSFLSEHNKPPPKSFHEEMLERRAQEEQQRLLEAKRKEEQEQREILHEIQRRKEEIKEEKKRKEMAKQERLEIASLSNQDHTSKKDPGGHRTAAILHGGSPDFVGNGKHRANSSGRSRRERQYSVCNSEDSPGSCEILYFNMGSPDQLMVHKGKCIGSDEQLGKLVYNALETATGGFVLLYEWVLQWQKKMGPFLTSQEKEKIDKCKKQIQGTETEFNSLVKLSHPNVVRYLAMNLKEQDDSIVVDILVEHISGVSLAAHLSHSGPIPVHQLRRYTAQLLSGLDYLHSNSVVHKVLSASNVLVDAEGTVKITDYSISKRLADICKEDVFEQTRVRFSDNALPYKTGKKGDVWRLGLLLLSLSQGQECGEYPVTIPSDLPADFQDFLKKCVCLDDKERWSPQQLLKHSFINPQPKMPLVEQSPEDSEGQDYVETVIPSNRLPSAAFFSETQRQFSRYFIEFEELQLLGKGAFGAVIKVQNKLDGCCYAVKRIPINPASRQFRRIKGEVTLLSRLHHENIVRYYNAWIERHERPAGPGTPPPDSGPLAKDDRAARGQPASDTDGLDSVEAAAPPPILSSSVEWSTSGERSASARFPATGPGSSDDEDDDEDEHGGVFSQSFLPASDSESDIIFDNEDENSKSQNQDEDCNEKNGCHESEPSVTTEAVHYLYIQMEYCEKSTLRDTIDQGLYRDTVRLWRLFREILDGLAYIHEKGMIHRDLKPVNIFLDSDDHVKIGDFGLATDHLAFSADSKQDDQTGDLIKSDPSGHLTGMVGTALYVSPEVQGSTKSAYNQKVDLFSLGIIFFEMSYHPMVTASERIFVLNQLRDPTSPKFPEDFDDGEHAKQKSVISWLLNHDPAKRPTATELLKSELLPPPQMEESELHEVLHHTLTNVDGKAYRTMMAQIFSQRISPAIDYTYDSDILKGNFSIRTAKMQQHVCETIIRIFKRHGAVQLCTPLLLPRNRQIYEHNEAALFMDHSGMLVMLPFDLRIPFARYVARNNILNLKRYCIERVFRPRKLDRFHPKELLECAFDIVTSTTNSFLPTAEIIYTIYEIIQEFPALQERNYSIYLNHTMLLKAILLHCGIPEDKLSQVYIILYDAVTEKLTRREVEAKFCNLSLSSNSLCRLYKFIEQKGDLQDLMPTINSLIKQKTGIAQLVKYGLKDLEEVVGLLKKLGIKLQVLINLGLVYKVQQHNGIIFQFVAFIKRRQRAVPEILAAGGRYDLLIPQFRGPQALGPVPTAIGVSIAIDKISAAVLNMEESVTISSCDLLVVSVGQMSMSRAINLTQKLWTAGITAEIMYDWSQSQEELQEYCRHHEITYVALVSDKEGSHVKVKSFEKERQTEKRVLETELVDHVLQKLRTKVTDERNGREASDNLAVQNLKGSFSNASGLFEIHGATVVPIVSVLAPEKLSASTRRRYETQVQTRLQTSLANLHQKSSEIEILAVDLPKETILQFLSLEWDADEQAFNTTVKQLLSRLPKQRYLKLVCDEIYNIKVEKKVSVLFLYSYRDDYYRILF
  
Inhibitor
Name:
BDBM50591056
Synonyms:
CHEMBL5180106
Type:
Small organic molecule
Emp. Form.:
C24H26BrN7O2
Mol. Mass.:
524.413
SMILES:
COCCNC(=O)[C@@H]1CC[C@@H](CC1)Nc1ncc2c(Br)nn(-c3ccc4ncccc4c3)c2n1 |r,wU:10.13,7.6,(-1.49,-4.94,;-2.82,-5.71,;-4.16,-4.94,;-5.49,-5.71,;-6.83,-4.94,;-6.83,-3.4,;-8.16,-2.63,;-5.49,-2.63,;-4.16,-3.4,;-2.82,-2.63,;-2.82,-1.09,;-4.16,-.32,;-5.49,-1.09,;-1.49,-.32,;-.16,-1.09,;-.16,-2.64,;1.18,-3.4,;2.51,-2.63,;3.97,-3.09,;4.37,-4.58,;4.89,-1.84,;4.01,-.62,;4.41,.86,;3.32,1.95,;3.72,3.44,;5.2,3.83,;5.6,5.31,;7.08,5.71,;8.16,4.64,;7.77,3.16,;6.29,2.75,;5.9,1.26,;2.51,-1.09,;1.18,-.32,)|
Structure:
Search PDB for entries with ligand similarity: